KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Acadia Pharmaceuticals (ACAD) EPS (Basic): 2009-2025

Historic EPS (Basic) for Acadia Pharmaceuticals (ACAD) over the last 17 years, with Sep 2025 value amounting to $0.43.

  • Acadia Pharmaceuticals' EPS (Basic) rose 115.00% to $0.43 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.57, marking a year-over-year increase of 101.28%. This contributed to the annual value of $1.37 for FY2024, which is 470.27% up from last year.
  • According to the latest figures from Q3 2025, Acadia Pharmaceuticals' EPS (Basic) is $0.43, which was up 168.75% from $0.16 recorded in Q2 2025.
  • In the past 5 years, Acadia Pharmaceuticals' EPS (Basic) ranged from a high of $0.87 in Q4 2024 and a low of -$0.70 during Q1 2022.
  • In the last 3 years, Acadia Pharmaceuticals' EPS (Basic) had a median value of $0.16 in 2025 and averaged $0.15.
  • As far as peak fluctuations go, Acadia Pharmaceuticals' EPS (Basic) tumbled by 135.29% in 2023, and later surged by 1,900.00% in 2024.
  • Quarterly analysis of 5 years shows Acadia Pharmaceuticals' EPS (Basic) stood at -$0.27 in 2021, then climbed by 3.70% to -$0.26 in 2022, then spiked by 207.69% to $0.28 in 2023, then soared by 210.71% to $0.87 in 2024, then soared by 115.00% to $0.43 in 2025.
  • Its EPS (Basic) was $0.43 in Q3 2025, compared to $0.16 in Q2 2025 and $0.11 in Q1 2025.